Company intelligence / Profile preview
Nanjing NingQi Medicine Science and Technology
Nanjing, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Nanjing NingQi Medicine Science and Technology is an active Chinese pharmaceutical company focused on oncology. It sponsors clinical trials for both traditional Chinese medicine formulations and modern biologics. Its lead programs include ChangTai Keli for colon cancer in Phase 2/3 studies, and Endostar combined with chemotherapy for advanced non-small cell lung squamous carcinoma in a Phase 4 trial. No recent published results are available; trial statuses are listed as "unknown."
- Therapeutic areas
- Oncology
- Modalities
- Traditional Chinese medicine formulationSmall moleculeRecombinant protein
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Nanjing NingQi Medicine Science and Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing NingQi Medicine Science and Technology.